OnabotulinumtoxinA Modulates Visual Cortical Excitability in Chronic Migraine: Effects of 12-Week Treatment

Toxins (Basel). 2022 Dec 29;15(1):23. doi: 10.3390/toxins15010023.

Abstract

Chronic migraine is a burdensome disease presenting with episodic pain and several symptoms that may persist even among headache attacks. Multisensory integration is modified in migraine, as assessed by the level of the perception of sound-induced flash illusions, a simple paradigm reflecting changes in cortical excitability which reveals to be altered in migraineurs. OnabotulinumtoxinA is an effective preventive therapy for chronic migraineurs, reducing peripheral and central sensitization, and may influence cortical excitability. Patients affected by chronic migraine who started onabotulinumtoxinA preventive therapy were included. Clinical effects (headache diaries and migraine related questionnaires) were assessed at the beginning of the therapy and after 12 weeks. Contextually, patients underwent the evaluation of multisensory perception by means of the sound-induced flash illusions. OnabotulinumtoxinA showed effectiveness both in migraine prevention and in reducing headache burden. Even one session of therapy was able to restore, at least partially, multisensory processing, as shown by patients' susceptibility to the sound-induced flash illusion. OnabotulinumtoxinA could influence migraineurs cortical excitability concurrently to the beneficial effects in headache prevention.

Keywords: chronic migraine; multisensory integration; neurophysiology; onabotulinumtoxinA; visual cortical excitability.

MeSH terms

  • Botulinum Toxins, Type A* / therapeutic use
  • Chronic Disease
  • Headache / drug therapy
  • Humans
  • Illusions*
  • Migraine Disorders* / prevention & control
  • Treatment Outcome

Substances

  • Botulinum Toxins, Type A

Grants and funding

This research received no external funding.